Replimune has initiated a Phase I clinical trial of its investigational candidate, RP2, as a monotherapy or in combination with Opdivo for the treatment of advanced solid tumours.

Based on the company’s Immulytic platform, RP2 expresses a genetically encoded protein that is similar to the anti-CTLA-4 antibody, along with the GALV-GP-R- fusogenic protein and GM-CSF.

The drug candidate is intended to prevent the inhibition of immune responses triggered by CTLA-4.

In preclinical studies, RP2 showed improved efficacy alone and in combination with anti-PD1 therapy.

Replimune co-founder, president and CEO Robert Coffin said: “CTLA-4 inhibition is an established mechanism of action for cancer treatment, including proven synergy with anti-PD1 therapy.

“By combining the expression of anti-CTLA-4 with oncolytic tumour destruction and antigen release directly in the tumour and draining lymph nodes, we believe that the efficacy of CTLA-4 inhibition can be enhanced with RP2, while reducing toxicity as compared to systemic administration.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The Phase I trial will evaluate the safety and tolerability of RP2 alone and in combination with Opdivo, an anti-PD1 therapy developed by Bristol-Myers Squibb (BMS).

It also aims to determine the optimal dose. The first patient for the trial has been enrolled.

Replimune partnered with BMS for the study. BMS provided a non-exclusive, non-transferable, royalty-free licence to Opdivo for use with RP2 and will also supply its drug free of charge.

Earlier this month, Replimune started patient enrolment in a Phase II trial of another Immulytic product candidate RP1 to treat cutaneous squamous cell carcinoma (CSCC).

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now